Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENICE: Aflibercept in Metastatic Castration-Resistant Prostate Cancer
NCT00519285Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2007
- Primary completion
- Apr 2012
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 31
01
Overview
A Phase 3 trial of aflibercept in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sanofi. Started Aug 2007; status: completed.
02
Drugs
aflibercept
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00519285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00519285.